Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives.

Ibogaine, a psychedelic compound distinct from psilocybin or LSD, has attracted interest for treating substance use and psychiatric disorders, but clinical evidence remains weak. A narrative review of studies from 1990 to 2025 found 24 studies and 38 case reports. Most positive efficacy data come from uncontrolled, open-label, or retrospective studies with high risk of bias. No double-blind randomized controlled trial has shown ibogaine or its metabolite noribogaine to effectively treat opioid use disorder. One small trial reported significant effects for cocaine use disorder. Observational data suggest possible symptom relief for opioid use disorder, PTSD, or polysubstance dependence, but findings are exploratory. Serious adverse events, especially cardiotoxicity from QT prolongation, pose considerable risk given unproven efficacy. Current evidence is insufficient to support clinical use.

Study at a glance

Abstract

Ibogaine has garnered interest for its potential therapeutic properties in substance use and psychiatric disorders. Unlike classic psychedelics such as psilocybin or LSD, ibogaine remains underexplored in clinical research. This review aimed to synthesize the clinical literature on ibogaine use in humans over the past 3 decades, focusing on outcomes and safety. We conducted a narrative review of studies on ibogaine's clinical use published from 1990 to February 2025, including randomized controlled trials (RCTs), open-label, retrospective, and observational studies. Databases were searched for reports on efficacy and safety across various indications. Twenty-four studies and 38 case reports/series were included. Most of the positive efficacy data come from uncontrolled, open-label, or retrospective studies, many conducted in nonclinical settings, with a high risk of bias. No double-blind RCT to date has demonstrated that ibogaine or noribogaine can effectively treat opioid use disorder (OUD). Only 1 small RCT reported significant effects for cocaine use disorder. Although observational data suggest that ibogaine may alleviate symptoms of OUD, PTSD, or polysubstance dependence, these findings remain exploratory. Moreover, serious ibogaine-related adverse events have been reported, especially cardiotoxicity due to QT prolongation, which represents a considerable risk given the currently unproven efficacy. While ibogaine remains a compound of interest for neuropsychiatric research, current evidence is insufficient to support its clinical use. Further studies are needed to better demonstrate ibogaine's efficacy, optimize its safety profile, and determine how it could be integrated into psychiatric care, especially in relation to the emerging therapeutic use of classic psychedelics.